Drug-Receptor Interaction: Pharmacodynamics & Dose-Response

Master pharmacodynamics: Learn about receptor theory, graded vs quantal dose-response curves, potency, efficacy, and therapeutic index calculation.

#pharmacology#pharmacodynamics#dose-response-curve#receptor-theory#agonists-antagonists#medical-education#drug-efficacy

Watch
Pitch

Quantitation of Drug-Receptor Interaction

& Elicited Effects

Pharmacodynamics | Receptor Theory | Dose-Response Relationships

Department of Pharmacology

Medical/Pharmacy Students

Made by

Lecture Outline

1. Introduction to Drug-Receptor Theory

2. Receptor Occupancy & Binding

3. Graded Dose-Response Curves

4. Quantal Dose-Response Curves

5. Efficacy, Potency & Affinity

6. Agonists, Antagonists & Partial Agonists

7. Therapeutic & Toxic Ratios

8. Clinical Relevance

Made by

Introduction to Drug-Receptor Theory

A receptor is a macromolecule (protein) that specifically binds a drug/ligand
Binding triggers a biological response (signal transduction)
Receptors can be membrane-bound, nuclear, or intracellular
Most drugs act by binding to specific receptors — "lock and key" model

"The receptor is the structural protein that senses the drug signal and converts it to a biological response."

Drug (Ligand)

Receptor

Cell Membrane

Second Messenger

Made by

Receptor Occupancy Theory

The Clark Model (1926)

Effect is proportional to the fraction of receptors occupied by drug
D + R ⇌ DR → Effect
At maximum effect, all receptors are occupied

Occupancy Formula

          Fractional Occupancy = [D] / (Kd + [D])
        

[D] = drug concentration | K_d = dissociation constant

Department of Pharmacology

Medical / Pharmacy Students

Made by

Graded Dose-Response Curves

Definition

• Measures the magnitude of response in a single subject/tissue
• Response increases gradually with increasing dose
• Plotted as: Effect (%) on Y-axis vs Log [Drug Dose] on X-axis
• Produces a characteristic S-shaped (sigmoidal) curve

Key Parameters from the Curve

Emax — Maximum possible effect
EC50 — Concentration producing 50% of Emax
Slope — Steepness of the dose-response curve

Made by

Quantal Dose-Response Curves

Definition

• Measures the proportion of a population that responds to a given dose
• All-or-nothing response (responds or does not respond)
• Plotted as: % Population Responding vs Log Dose
• Results in a cumulative S-shaped curve

Key Statistical Parameters

• ED50 — Dose effective in 50% of population
• TD50 — Dose toxic in 50% of population
• LD50 — Lethal dose in 50% of population
• These parameters are derived from the quantal DRC

Made by

Potency & Efficacy

Potency

The amount of drug needed to produce a given effect. Measured by EC₅₀ — lower EC₅₀ = higher potency.

Drug A (EC₅₀=1mg) is MORE potent than Drug B (EC₅₀=10mg)

Note Potency ≠ Safety

Efficacy (E_max)

The maximum effect a drug can produce regardless of dose. Intrinsic property of the drug-receptor interaction.

A drug with higher E_max has greater intrinsic efficacy

Note Efficacy is clinically more important than potency

Affinity (K_d)

The strength of binding between drug and receptor. Low K_d = High affinity = strong binding.

K_d = [D][R] / [DR]

Note Inversely related to K_d value

Made by

Agonists & Antagonists

AGONISTS

Full Agonist

Binds receptor and produces MAXIMUM response.

High intrinsic efficacy (α=1)

Example: Morphine, Adrenaline

Partial Agonist

Binds receptor but produces SUBMAXIMAL response.

Intermediate intrinsic efficacy (0<α<1)

Example: Buprenorphine

Inverse Agonist

Binds receptor and produces OPPOSITE effect.

Negative intrinsic efficacy (α<0)

Example: β-carbolines

ANTAGONISTS

Competitive Antagonist

•

Competes with agonist for same receptor site.

•

Effect REVERSIBLE by increasing agonist concentration.

•

Shifts DRC to the right (parallel shift).

Example: Atropine, Naloxone

Non-competitive Antagonist

•

Binds irreversibly or at allosteric site.

•

DEPRESSES Emax. Cannot be overcome by increasing agonist.

Example: Phenoxybenzamine

Made by

Competitive vs Non-Competitive Antagonism

Competitive Antagonism

• Antagonist competes with agonist at SAME binding site
• Effect overcome by increasing agonist dose
• Parallel RIGHTWARD shift of dose-response curve
• Emax is UNCHANGED
• Example: Atropine blocking muscarinic receptors

Emax Preserved

Non-Competitive Antagonism

• Antagonist binds DIFFERENT site (allosteric) or irreversibly
• Effect CANNOT be overcome by increasing agonist
• Curve shifts: Emax is REDUCED/DEPRESSED
• EC50 may be unchanged
• Example: Phenoxybenzamine (alpha blockers)

Emax Reduced

Made by

Therapeutic Index & Safety Ratios

Therapeutic Index (TI)

A measure of drug safety — ratio of toxic dose to effective dose.

TI = TD50 / ED50

(or in animal studies: TI = LD₅₀ / ED₅₀)

Higher TI = Safer drug (wider margin between effective and toxic doses)

Certain Safety Factor (CSF)

CSF = TD₁ / ED₉₉

More conservative — uses the lowest toxic dose vs highest effective dose

Therapeutic Window

Range of doses between minimum effective concentration (MEC) and minimum toxic concentration (MTC). Drug must stay within this range for optimal therapy.

Dose (log scale)

Toxic Zone

TD₅₀

Minimum Toxic Concentration (MTC)

Therapeutic
Window

ED₅₀

Minimum Effective Concentration (MEC)

Sub-therapeutic

Pharmacology Fundamentals

Pharmacokinetics & Dynamics

Made by

Spare Receptors & Receptor Reserve

Concept of Spare Receptors

Maximum effect can be achieved even when only a FRACTION of receptors are occupied
Remaining unoccupied receptors are called "spare receptors" or "receptor reserve"
First demonstrated by Stephenson (1956)
Spare receptors increase sensitivity to agonist (leftward shift of DRC)

Implications

EC₅₀ < K_d (EC₅₀ is lower than dissociation constant)
Even if some receptors are blocked, full response may still occur
Tissues with more spare receptors are more sensitive to agonists
Important in understanding tolerance and drug resistance

Total Receptors (100%)

10%

90%

Receptors needed
for E_max

Spare Receptors

Department of Pharmacology

Medical/Pharmacy Students

Made by

Signal Transduction & Downstream Effects

Ion Channel-Linked Receptors

Direct ion flow on binding.

Speed: Fast response (milliseconds)

Example: nAChR, GABA-A

Effect: Membrane depolarization / hyperpolarization

G-Protein Coupled Receptors (GPCRs)

Most common receptor type. Coupled to second messengers (cAMP, IP3, DAG).

Speed: Moderate speed (seconds)

Example: Adrenergic, muscarinic receptors

Effect: Activation of downstream paths

Enzyme-Linked Receptors

Tyrosine kinase activity on binding.

Speed: Slower response (minutes-hours)

Example: Insulin receptor, growth factor receptors

Effect: Gene expression changes

Pathway Overview

Drug

➜

Receptor Binding

➜

Signal Transduction

➜

Second Messenger

➜

Effector Protein

➜

Biological Effect

Made by

Drug Tolerance & Desensitization

Tolerance

• Decreased response to a drug over time with repeated exposure
• Requires increasing doses to achieve the same effect
• Types: Pharmacokinetic (metabolic), Pharmacodynamic (receptor-level)
• Example: Opioid tolerance, alcohol tolerance, nitrate tolerance

Receptor Desensitization

• Loss of receptor responsiveness despite continued drug presence
• Mechanisms: receptor phosphorylation, internalization, uncoupling from G-protein
• Tachyphylaxis: rapid onset desensitization
• Example: Beta-adrenergic receptor desensitization with prolonged β-agonist use

Chart

Receptor Internalization

Made by

Key Takeaways

🔬 Drug effects are quantified through dose-response relationships

📈 Graded DRCs measure magnitude; Quantal DRCs measure population response

🎯 EC50 reflects potency; Emax reflects efficacy

⚖️ Therapeutic Index = TD50/ED50 — key safety measure

🔗 Competitive antagonism shifts DRC right; non-competitive reduces Emax

💊 Spare receptors allow maximal effect with partial receptor occupancy

🔄 Tolerance/desensitization reduce drug response over time

🧬 Signal transduction links receptor binding to biological effects

Understanding receptor quantitation is fundamental to rational drug design and clinical pharmacotherapy.

Department of Pharmacology

Thank You

Made by

DESIGNER-MADE
PRESENTATION,
GENERATED FROM
YOUR PROMPT

Create your own professional slide deck with real images, data charts, and unique design in under a minute.

Generate For Free

Drug-Receptor Interaction: Pharmacodynamics & Dose-Response

Master pharmacodynamics: Learn about receptor theory, graded vs quantal dose-response curves, potency, efficacy, and therapeutic index calculation.

Quantitation of Drug-Receptor Interaction

& Elicited Effects

Pharmacodynamics | Receptor Theory | Dose-Response Relationships

Department of Pharmacology

Medical/Pharmacy Students

Lecture Outline

Introduction to Drug-Receptor Theory

Receptor Occupancy & Binding

Graded Dose-Response Curves

Quantal Dose-Response Curves

Efficacy, Potency & Affinity

Agonists, Antagonists & Partial Agonists

Therapeutic & Toxic Ratios

Clinical Relevance

Introduction to Drug-Receptor Theory

A receptor is a macromolecule (protein) that specifically binds a drug/ligand

Binding triggers a biological response (signal transduction)

Receptors can be membrane-bound, nuclear, or intracellular

Most drugs act by binding to specific receptors — "lock and key" model

"The receptor is the structural protein that senses the drug signal and converts it to a biological response."

Drug (Ligand)

Receptor

Cell Membrane

Second Messenger

Receptor Occupancy Theory

The Clark Model (1926)

Effect is proportional to the fraction of receptors occupied by drug

D + R ⇌ DR → Effect

At maximum effect, all receptors are occupied

Occupancy Formula

Fractional Occupancy = [D] / (Kd + [D])

drug concentration

dissociation constant

Department of Pharmacology

Medical / Pharmacy Students

Graded Dose-Response Curves

Definition

Measures the magnitude of response in a single subject/tissue

Response increases gradually with increasing dose

Plotted as: Effect (%) on Y-axis vs Log [Drug Dose] on X-axis

Produces a characteristic S-shaped (sigmoidal) curve

Key Parameters from the Curve

Emax

Maximum possible effect

EC50

Concentration producing 50% of Emax

Slope

Steepness of the dose-response curve

Quantal Dose-Response Curves

Definition

Measures the proportion of a population that responds to a given dose

All-or-nothing response (responds or does not respond)

Plotted as: % Population Responding vs Log Dose

Results in a cumulative S-shaped curve

Key Statistical Parameters

ED50 — Dose effective in 50% of population

TD50 — Dose toxic in 50% of population

LD50 — Lethal dose in 50% of population

These parameters are derived from the quantal DRC

Potency & Efficacy

Potency

The amount of drug needed to produce a given effect. Measured by EC50 — lower EC50 = higher potency.

Drug A (EC50=1mg) is MORE potent than Drug B (EC50=10mg)

Potency ≠ Safety

Efficacy (Emax)

The maximum effect a drug can produce regardless of dose. Intrinsic property of the drug-receptor interaction.

A drug with higher Emax has greater intrinsic efficacy

Efficacy is clinically more important than potency

Affinity (Kd)

The strength of binding between drug and receptor. Low Kd = High affinity = strong binding.

Kd = [D][R] / [DR]

Inversely related to Kd value

Agonists & Antagonists

AGONISTS

ANTAGONISTS

Full Agonist

Binds receptor and produces MAXIMUM response.

High intrinsic efficacy (α=1)

Example: Morphine, Adrenaline

Partial Agonist

Binds receptor but produces SUBMAXIMAL response.

Intermediate intrinsic efficacy (0<α<1)

Example: Buprenorphine

Inverse Agonist

Binds receptor and produces OPPOSITE effect.

Negative intrinsic efficacy (α<0)

Example: β-carbolines

Competitive Antagonist

Competes with agonist for same receptor site.

Effect REVERSIBLE by increasing agonist concentration.

Shifts DRC to the right (parallel shift).

Example: Atropine, Naloxone

Non-competitive Antagonist

Binds irreversibly or at allosteric site.

DEPRESSES Emax. Cannot be overcome by increasing agonist.

Example: Phenoxybenzamine

Competitive vs Non-Competitive Antagonism

Competitive Antagonism

Non-Competitive Antagonism

Therapeutic Index & Safety Ratios

Therapeutic Index (TI)

A measure of drug safety — ratio of toxic dose to effective dose.

TI = TD50 / ED50

(or in animal studies: TI = LD50 / ED50)

Higher TI = Safer drug (wider margin between effective and toxic doses)

Certain Safety Factor (CSF)

CSF = TD1 / ED99

More conservative — uses the lowest toxic dose vs highest effective dose

Therapeutic Window

Range of doses between minimum effective concentration (MEC) and minimum toxic concentration (MTC). Drug must stay within this range for optimal therapy.

Pharmacology Fundamentals

Pharmacokinetics & Dynamics

Spare Receptors & Receptor Reserve

Concept of Spare Receptors

Implications

Maximum effect can be achieved even when only a FRACTION of receptors are occupied

Remaining unoccupied receptors are called "spare receptors" or "receptor reserve"

First demonstrated by Stephenson (1956)

Spare receptors increase sensitivity to agonist (leftward shift of DRC)

EC50 < Kd (EC50 is lower than dissociation constant)

Even if some receptors are blocked, full response may still occur

Tissues with more spare receptors are more sensitive to agonists

Important in understanding tolerance and drug resistance

Total Receptors (100%)

Department of Pharmacology

Medical/Pharmacy Students

Signal Transduction & Downstream Effects

Ion Channel-Linked Receptors

Direct ion flow on binding.

Fast response (milliseconds)

nAChR, GABA-A

Membrane depolarization / hyperpolarization

G-Protein Coupled Receptors (GPCRs)

Most common receptor type. Coupled to second messengers (cAMP, IP3, DAG).

Moderate speed (seconds)

Adrenergic, muscarinic receptors

Activation of downstream paths

Enzyme-Linked Receptors

Tyrosine kinase activity on binding.

Slower response (minutes-hours)

Insulin receptor, growth factor receptors

Gene expression changes

Drug

Receptor Binding

Signal Transduction

Second Messenger

Effector Protein

Biological Effect

Drug Tolerance & Desensitization

Tolerance

Decreased response to a drug over time with repeated exposure

Requires increasing doses to achieve the same effect

Types: Pharmacokinetic (metabolic), Pharmacodynamic (receptor-level)

Opioid tolerance, alcohol tolerance, nitrate tolerance

Receptor Desensitization

Loss of receptor responsiveness despite continued drug presence

Mechanisms: receptor phosphorylation, internalization, uncoupling from G-protein

Tachyphylaxis: rapid onset desensitization

Beta-adrenergic receptor desensitization with prolonged β-agonist use

Key Takeaways

🔬 Drug effects are quantified through dose-response relationships

📈 Graded DRCs measure magnitude; Quantal DRCs measure population response

🎯 EC50 reflects potency; Emax reflects efficacy

⚖️ Therapeutic Index = TD50/ED50 — key safety measure

🔗 Competitive antagonism shifts DRC right; non-competitive reduces Emax

💊 Spare receptors allow maximal effect with partial receptor occupancy

🔄 Tolerance/desensitization reduce drug response over time

🧬 Signal transduction links receptor binding to biological effects

Understanding receptor quantitation is fundamental to rational drug design and clinical pharmacotherapy.

Department of Pharmacology

Thank You

pharmacology
pharmacodynamics
dose-response-curve
receptor-theory
agonists-antagonists
medical-education
drug-efficacy

Quantitation of Drug-Receptor Interaction

& Elicited Effects

Lecture Outline

Introduction to Drug-Receptor Theory

Receptor Occupancy Theory

The Clark Model (1926)

Occupancy Formula

Graded Dose-Response Curves

Definition

Key Parameters from the Curve

Quantal Dose-Response Curves

Definition

Key Statistical Parameters

Potency & Efficacy

Potency

Efficacy (Emax)

Affinity (Kd)

Agonists & Antagonists

AGONISTS

Full Agonist

Partial Agonist

Inverse Agonist

ANTAGONISTS

Competitive Antagonist

Non-competitive Antagonist

Competitive vs Non-Competitive Antagonism

Competitive Antagonism

Non-Competitive Antagonism

Therapeutic Index & Safety Ratios

Therapeutic Index (TI)

Certain Safety Factor (CSF)

Therapeutic Window

Spare Receptors & Receptor Reserve

Concept of Spare Receptors

Implications

Signal Transduction & Downstream Effects

Ion Channel-Linked Receptors

G-Protein Coupled Receptors (GPCRs)

Enzyme-Linked Receptors

Drug Tolerance & Desensitization

Tolerance

Receptor Desensitization

Key Takeaways

DESIGNER-MADE PRESENTATION, GENERATED FROM YOUR PROMPT

Drug-Receptor Interaction: Pharmacodynamics & Dose-Response

Efficacy (E_max)

Affinity (K_d)

DESIGNER-MADE
PRESENTATION,
GENERATED FROM
YOUR PROMPT